Jaguar Health Community

NasdaqCM:JAGX Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments

Key Takeaways New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments. Expanding product indications and strategic launches aim to address unmet needs, potentially boosting revenue and elevating demand within targeted oncology markets.

US$150.00

FV

92.7% undervalued

35.75%

Revenue growth p.a.

0

0

4

5 days ago